| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Pioglitazone (potassium salt) Basic information |
| Product Name: | Pioglitazone (potassium salt) | | Synonyms: | Pioglitazone (potassium salt);potassium:5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione;Pioglitazone potassium | | CAS: | 1266523-09-4 | | MF: | C19H21KN2O3S | | MW: | 396.55 | | EINECS: | | | Product Categories: | | | Mol File: | 1266523-09-4.mol |  |
| | Pioglitazone (potassium salt) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 10 mg/ml; Ethanol: 10 mg/ml | | form | A crystalline solid |
| | Pioglitazone (potassium salt) Usage And Synthesis |
| Uses | Pioglitazone (U 72107) potassium is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium can be used in diabetes research[2][3][4]. | | in vivo | Pioglitazone potassium (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle[3].
Pioglitazone potassium (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia[4].
| Animal Model: | ob/ob and adipo-/- ob/ob mice with a C57Bl/6 background[3] | | Dosage: | 10 or 30 mg/kg | | Administration: | Oral gavage; once daily; 14 days | | Result: | Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg.
Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.
|
| Animal Model: | Male Wistar albino rats[4] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; once daily; 4 weeks | | Result: | Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system. |
| | IC 50 | mouse PPARγ: 0.99 μM (EC50); h-PPARγ: 0.93 μM (EC50); hPPARδ: 43 μM (EC50); hPPARα: 100 μM (EC50); mouse PPARα: 100 μM (EC50) | | References | [1] Kenji Kuwabara, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist,2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J Pharmacol Exp Ther. 2004 Jun;309(3):970-7. DOI:10.1124/jpet.103.064659
[2] A Puddu, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. DOI:10.1016/j.regpep.2012.05.089
[3] Naoto Kubota, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. DOI:10.1074/jbc.M505649200
[4] Rania A Elrashidy, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. DOI:10.1177/1074248411431581 |
| | Pioglitazone (potassium salt) Preparation Products And Raw materials |
|